Rising Prevalence of Metabolic Dysfunction - Associated Steatotic Liver Disease in an urban South Indian screening cohort: a Retrospective Cross-sectional Study.
Nov 2026· Annals of Epidemiology· Vol 124, pp.
110309
· 0 citations· 20 references
Medicine
TL;DR
Nearly two-thirds of asymptomatic urban South Indian adults screened met MASLD criteria, predominantly working-age individuals under-detected by conventional tools, suggesting FibroScan-based screening should be considered in preventive health programmes to enable earlier detection.
Abstract
Purpose
Metabolic dysfunction-associated steatotic liver disease (MASLD), redefined in 2023 from non-alcoholic fatty liver disease, is highly prevalent globally, but population-level data using 2023 AASLD criteria and FibroScan-based assessment remain scarce in South Asia, particularly among asymptomatic adults undergoing routine health screening.
Methods
We conducted a retrospective cross-sectional study of 1,103 asymptomatic adults (mean age 43.1±12.7 years; 64.1% male) undergoing FibroScan-based Master Health Check-up at a tertiary centre in Chennai, India (2023-2025). MASLD was defined as controlled attenuation parameter (CAP) ≥249 dB/m plus ≥1 cardiometabolic risk factor; fibrosis was assessed by liver stiffness measurement (LSM).
Results
MASLD was identified in 716 participants (64.9%; 95% CI 62.1-67.7%). Affected individuals were older, had higher BMI, and more frequently had diabetes, hypertension, and dyslipidaemia (all p<0.01). In multivariable analysis, age, male sex, BMI, and diabetes were independently associated with MASLD. Notably, 53.4% of cases occurred in adults under 46 years, and 45.3% had normal liver function tests while 31.3% had normal ultrasound, indicating conventional screening substantially underestimates disease burden.
Conclusions
Nearly two-thirds of asymptomatic urban South Indian adults screened met MASLD criteria, predominantly working-age individuals under-detected by conventional tools. FibroScan-based screening should be considered in preventive health programmes to enable earlier detection.
Background The influence of sex and age on the prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD) among hospitalized patients remains unclear. Methods This cross-sectional study included 136,816 hospitalized adults (2014–2023) at the People’s Hospital of Guangxi Zhuang Autonomous Region. Hep...
Zhe-Min Liu, Suo-Su Wei· Frontiers in Endocrinology· 0 citations
Obesity, diabetes, and metabolic syndrome are becoming increasingly prevalent in Saudi Arabia, and therefore, raising concerns about metabolic dysfunction-associated steatotic liver disease (MASLD), metabolic steatohepatitis (MASH), and related cardiovascular complications. This study compared the occurrence of a...
Reem K. AlManea, Kossay El-Abd, Sara H. Alsinan et al.· Journal of Family and Commun...· 0 citations
The findings endorse the need for screening for liver fibrosis in T2DM patients, particularly those at increased risk, and suggest early detection and appropriate management are essential to prevent progression to advanced liver disease.
M. Almohammadi, Z. E. Alsadi, A. B. Alenezi et al.· PeerJ· 0 citations
Objective: Screening for advanced fibrosis (AF) due to metabolic dysfunction-associated steatotic liver disease (MASLD) is recommended in diabetology. This study aimed to compare the performance of non-invasive tests (NITs) and 2-step algorithms for detecting patients with high-risk AF requiring referral to hepatologis...
C. Caussy, B. Vergès, Damien Leleu et al.· American Diabetes Associatio...· 0 citations
BACKGROUND
Metabolic dysfunction-associated steatotic liver disease (MASLD) is a growing public health challenge, highlighting the need for accessible markers of metabolic liver disease risk. Serum uric acid (SUA) has been linked to metabolic dysfunction, but its association with MASLD across the full clinical spectrum...
Hafiz M. Ahmed, Umm E. Aimen· Metabolic Syndrome and Relat...· 0 citations
Adiposity-related parameters and dyslipidemia appear to be important clinical features associated with hepatic steatosis in pediatric T1DM, which had a higher prevalence of CAP-based hepatic steatosis/MASLD than healthy controls.
Hanife Ayşegül Arsoy, Ö. Kara, Murat Keskin et al.· Journal of Clinical Research...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.